N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE manufacturers
- SB228357
-
- $41.00 / 1mg
-
2025-08-22
- CAS:181629-93-6
- Min. Order:
- Purity: 99.31%
- Supply Ability: 10g
|
| N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE Basic information |
Product Name: | N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE | Synonyms: | N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE;SB 228357;N-[3-Fluoro-5-(3-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide;N-[3-fluoro-5-(3-pyridinyl)phenyl]-5-methoxy-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide;1H-Indole-1-carboxamide, N-[3-fluoro-5-(3-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-;SB-228357,SB228357;SB228357, 10 mM in DMSO | CAS: | 181629-93-6 | MF: | C22H17F4N3O2 | MW: | 431.38 | EINECS: | | Product Categories: | | Mol File: | 181629-93-6.mol | ![N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE Structure](CAS/GIF/181629-93-6.gif) |
| N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE Chemical Properties |
Boiling point | 625.4±55.0 °C(Predicted) | density | 1.398±0.06 g/cm3(Predicted) | storage temp. | 2-8°C | solubility | DMSO: ~8 mg/mL, soluble | form | solid | pka | 9.72±0.70(Predicted) | color | white |
| N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE Usage And Synthesis |
Uses | SB 228357 is a SR-2C/SR-2B receptor antagonist. It is used in the treatment of irritable bowel syndrome (IBS). | Definition | ChEBI: SB 228357 is an indolyl carboxylic acid. | Biological Activity | 5-HT 2C/2B receptor antagonist (pK i values are 7.0, 8.1 and 9.1 at 5-HT 2A , 2B and 2C receptors respectively). Displays inverse agonism in a 5-HT-stimulated PI hydrolysis model of 5-HT 2C receptor function. Orally active in vivo . | in vivo | SB228357 (0-10 mg/kg; oral administration; for 90 minutes; male Sprague Dawley rats) treatment significantly reverses Haloperidol-induced catalepsy[2]. Animal Model: | Male Sprague Dawley rats (200-250?g) injected with Haloperidol[2] | Dosage: | 0 mg/kg, 0.32 mg/kg, 1 mg/kg, 3.2 mg/kg, 10 mg/kg | Administration: |
Oral administration; for 90 minutes | Result: | Significantly reversed Haloperidol-induced catalepsy.
|
| IC 50 | 5-HT2A Receptor: 6.9 (pKi); 5-HT2C Receptor: 9 (pKi); 5-HT2B Receptor: 8 (pKi) | storage | Store at RT |
| N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE Preparation Products And Raw materials |
|